Visa's Growth Prospects Remain Strong Despite Core Payment Deceleration; Analyst Reiterates Buy Rating
Maintaining Hold: Visa's Q3 Underperformance and Decelerating Growth Prompt Cautious Outlook
Deutsche Bank Adjusts Price Target on Goldman Sachs Group to $500 From $400, Maintains Hold Rating
Buy Rating Affirmed for Visa: Strong Q3 Growth and Positive Outlook Despite Headwinds
Visa (V) Gets a Buy From UBS
Piper Sandler Adjusts Price Target on Visa to $319 From $322, Maintains Overweight Rating
China Renaissance Adjusts Price Target on Microsoft to $520 From $470, Maintains Buy Rating
Visa Analyst Ratings
Maintaining Hold on Visa: Assessing Slowing Growth and Competitive Pressures
Analysts Offer Insights on Financial Companies: Chubb (CB), MSCI (MSCI) and Visa (V)
Goldman Sachs Remains a Buy on Visa (V)
TD Cowen Maintains Visa(V.US) With Buy Rating, Cuts Target Price to $318
KBW Maintains Visa(V.US) With Buy Rating, Maintains Target Price $325
KBW Reaffirms Their Buy Rating on Visa (V)
Visa Maintains Buy Rating Amid Consistent Performance and Growth Prospects
Cantor Fitzgerald Maintains UnitedHealth(UNH.US) With Buy Rating, Maintains Target Price $591
UnitedHealth Group Analyst Ratings
Redburn Atlantic Adjusts Price Target on Goldman Sachs to $450 From $400
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $360
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344